HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED Hansoh Pharmaceutical Group Company Limited Share Price BOERSE MUENCHEN
Equities
3KY
KYG549581067
Pharmaceuticals
|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.94 EUR | -2.02% |
|
-5.71% | +13.79% |
| 04-29 | Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024 | CI |
| 04-03 | Hansoh Pharmaceutical Secures Chinese Nod for Trial of Anti-Cancer Drug | MT |
| Sales 2024 * | 11.82B 1.63B 1.51B 128B | Sales 2025 * | 12.49B 1.72B 1.6B 136B | Capitalization | 89.35B 12.33B 11.41B 971B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.74B 516M 478M 40.65B | Net income 2025 * | 3.81B 525M 487M 41.38B | EV / Sales 2024 * | 5.76 x |
| Net cash position 2024 * | 21.23B 2.93B 2.71B 231B | Net cash position 2025 * | 23.86B 3.29B 3.05B 259B | EV / Sales 2025 * | 5.24 x |
| P/E ratio 2024 * |
23.5
x | P/E ratio 2025 * |
23.3
x | Employees | - |
| Yield 2024 * |
1.02% | Yield 2025 * |
1.06% | Free-Float | 18.24% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 week | -5.71% | ||
| Current month | -4.81% | ||
| 1 month | -2.94% | ||
| 3 months | +26.92% | ||
| 6 months | +10.61% | ||
| Current year | +13.79% |
1 week
1.94
2.06
1 month
1.942.18
3 years
1.153.60
| Managers | Title | Age | Since |
|---|---|---|---|
Hui Juan Zhong
CEO | Chief Executive Officer | 63 | 01/12/15 |
Sheng Li Zhong
SEC | Corporate Secretary | 56 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Guo Qiang Lin
BRD | Director/Board Member | 81 | 30/05/19 |
Sheung Wai Chan
BRD | Director/Board Member | 70 | 13/06/19 |
Dong Tao Yang
BRD | Director/Board Member | 67 | - |
| Date | Price | Change |
|---|---|---|
| 29/05/24 | 1.94 | -2.02% |
| 28/05/24 | 1.98 | 0.00% |
| 27/05/24 | 1.98 | 0.00% |
| 24/05/24 | 1.98 | -2.94% |
| 23/05/24 | 2.04 | 0.00% |
Real-time BOERSE MUENCHEN, May 29, 2024 at 08:43 pm
More quotes
Hansoh Pharmaceutical Group Company Limited specializes in the development, manufacture and marketing of pharmaceutical products for the treatment of tumor, infectious, metabolic and autoimmune diseases. Net sales break down by revenue source as follows:
- sales of pharmaceutical products (99.1%);
- sales of research and development services (0.9%).
Sector
Pharmaceuticals
Calendar
28/08/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
15.09
CNY
Average target price
17.81
CNY
Spread / Average Target
+18.08%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +39.22% | 727B | |
| +30.57% | 592B | |
| -7.85% | 347B | |
| +15.48% | 319B | |
| -0.12% | 274B | |
| +12.55% | 238B | |
| +6.65% | 204B | |
| -6.09% | 203B | |
| -3.37% | 160B |
- Stock Market
- Equities
- 3692 Stock
- 3KY Stock
